2304711-81-5
2304711-81-5
Chemical Structure
Frenlosirsen
Synonym(s): ION-935918; ION251
- CAS No.: 2304711-81-5
- Formula:C177H226N63O89P15S15
- Molecular Weight:5605.63
SMILES: [Frenlosirsen]
Biological Activity: Frenlosirsen (ION-935918; ION251) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen is applicable to myeloma-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Frenlosirsen | 96.46% | Frenlosirsen (ION-935918; ION251) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen is applicable to myeloma-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hartman JD, et al. Optimal conditions for quantification of IRF4 mRNA and protein as a correlative biomarker in clinical cancer studies. Journal of translational medicine. 2026 Mar 16;24(1):575. [Content Brief]
- [2]. Tong A A, et al. Abstract CT146: Safety, tolerability and molecular correlates of the IRF4-targeted antisense oligonucleotide frenlosirsen in patients with relapsed/refractory multiple myeloma: A phase 1a dose escalation trial. Cancer Research, 2025, 85(8_Supplement_2): CT146.
Keywords
